Anzeige
Mehr »
Login
Donnerstag, 03.04.2025 Börsentäglich über 12.000 News von 693 internationalen Medien
Warum Almonty Industries zum Schlüsselplayer für NATO-Staaten wird
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2DNMQ | ISIN: KYG108301006 | Ticker-Symbol:
NASDAQ
01.04.25
17:32 Uhr
1,550 US-Dollar
0,000
0,00 %
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BEYONDSPRING INC Chart 1 Jahr
5-Tage-Chart
BEYONDSPRING INC 5-Tage-Chart

Aktuelle News zur BEYONDSPRING Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
27.03.BeyondSpring GAAP EPS of -$0.211
27.03.BeyondSpring Inc. Full Year Loss Declines1
27.03.BeyondSpring, Inc.: BeyondSpring Reports 2024 Year-End Financial Results and Highlights Key Clinical & Strategic Milestones80Plinabulin Final Phase 3 Data Published in The Lancet Respiratory Medicine, Demonstrating Overall Survival Benefit in 2L/3L NSCLC EGFR Wild Type vs. DocetaxelPlinabulin Phase 2 Data Highlights Potential...
► Artikel lesen
27.03.BeyondSpring Inc. - 10-K, Annual Report1
27.03.BeyondSpring, Inc.: BeyondSpring Files 2024 Annual Report on Form 10-K1
27.03.BeyondSpring Inc. - 8-K, Current Report3
25.02.BeyondSpring Inc. - 8-K, Current Report-
BEYONDSPRING Aktie jetzt für 0€ handeln
28.01.BeyondSpring sells stake in preferred shares of SEED Therapeutics for ~$35.4M1
28.01.BeyondSpring sells SEED Therapeutics shares for $35.4M2
28.01.BeyondSpring, Inc.: BeyondSpring Announces $35.4 Million Sale of a Portion of Equity Interest in SEED Therapeutics to Advance Lead Asset Plinabulin to Anti-Cancer Registrational Studies2
28.01.BeyondSpring Inc. - 8-K, Current Report-
03.01.BeyondSpring Inc. - 8-K, Current Report-
11.11.24BeyondSpring, Inc.: BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior ...138FLORHAM PARK, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company developing innovative cancer...
► Artikel lesen
16.09.24BeyondSpring, Inc.: BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024189FLORHAM PARK, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company developing innovative cancer...
► Artikel lesen
16.09.24BeyondSpring, Inc.: BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024156FLORHAM PARK, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company developing innovative cancer...
► Artikel lesen
06.08.24BeyondSpring, Inc.: SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications214The SEED-Eisai Research Collaboration leverages Eisai's leading expertise in neurodegeneration and cancer. SEED is entitled to receive upfront and milestone payments of up to $1.5 billion plus tiered...
► Artikel lesen
29.04.24BeyondSpring, Inc.: BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results231- BeyondSpring Dosed First Patient of Two Phase 2 Investigator-Initiated Trials (IIT) in Plinabulin and Keytruda Combination Studies - SITC 2023 Presentation of the Phase 1 Topline Clinical and Mechanism...
► Artikel lesen
17 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1